Sanofi (SNY) vs Zoetis (ZTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sanofi (SNY) has outperformed Zoetis (ZTS) over the past year, losing 17.6% versus a loss of 49.1%. Over five years, SNY leads with a -17.6% price change compared with -63.9% for ZTS. Sanofi is the larger company by market cap ($96.19 billion vs $30.77 billion), about 3.1 times the size.
On valuation, Sanofi trades at a lower forward P/E (7.4x vs 11.4x for Zoetis). Sanofi offers the higher dividend yield (10.26% vs 2.77%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SNY | ZTS |
|---|---|---|
| Share price | $40.15 | $74.46 |
| Market cap | $96.19B | $30.77B |
| 1-day change | -0.21% | +1.88% |
| YTD return | -16.98% | -41.92% |
| 1-year return | -17.56% | -49.07% |
| 5-year return | -17.65% | -63.86% |
| P/E ratio (TTM) | 21.13 | 12.25 |
| Forward P/E | 7.43 | 11.38 |
| EPS (TTM) | $1.90 | $6.08 |
| Dividend yield | 10.26% | 2.77% |
| Annual dividend | $4.12 | $2.06 |
| Revenue (latest FY) | — | $9.47B |
| Revenue growth (YoY) | — | +2.28% |
| Net income (latest FY) | — | $2.67B |
| Gross margin | — | 71.84% |
| Net margin | — | 28.23% |
| 52-week high | $52.68 | $148.30 |
| 52-week low | $39.18 | $68.77 |
| Distance from 52-week high | -23.79% | -49.79% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +33.54% | +28.94% |
| Average volume | 2.87M | 5.46M |
| Shares outstanding | 2.40B | 413.22M |
| Employees | 74,846 | 14,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Sanofi is about 3.1 times larger than Zoetis by market value ($96.19B vs $30.77B).
- SNY has outperformed ZTS by 31.5 percentage points over the past year.
- Sanofi trades at a higher earnings multiple (21.1x vs 12.2x trailing P/E).
- Sanofi offers a meaningfully higher dividend yield (10.26% vs 2.77%).
About Sanofi
SNY stock →Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Health Care · Biotechnology: Pharmaceutical Preparations · 74,846 employees
About Zoetis
ZTS stock →Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 14,500 employees
SNY vs ZTS FAQ
Which is bigger, Sanofi or Zoetis?
Sanofi (SNY) is larger, with a market capitalization of $96.19B compared with $30.77B for Zoetis (ZTS).
Which stock has performed better over the past year, SNY or ZTS?
SNY returned -17.56% over the past 12 months, compared with -49.07% for ZTS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, SNY or ZTS?
ZTS has the lower trailing P/E at 12.2, versus 21.1 for SNY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Sanofi or Zoetis?
Sanofi has the higher yield at 10.26%, compared with 2.77% for Zoetis.
Are Sanofi and Zoetis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.